Association of Fasting Plasma Glucose Trajectory with Lifetime Risk of Cardiovascular Disease

Dankang Li,Lulu Song,Lulin Wang,Shuohua Chen,Yingping Yang,Yonghua Hu,Youjie Wang,Shouling Wu,Yaohua Tian

DOI: https://doi.org/10.1038/s41430-022-01243-x

2022-01-01

European Journal of Clinical Nutrition

Abstract:Background Few studies have used multiple measurements of fasting plasma glucose (FPG) to examine the impact of long-term FPG trajectory patterns on lifetime risk of cardiovascular disease (CVD). We aimed to identify the long-term patterns in FPG trajectories and to estimate the lifetime risk of CVD according to FPG trajectories. Methods Individuals free of CVD at index ages 35 ( n = 72,324), 45 ( n = 62,049), and 55 ( n = 38,113) years were included. FPG concentrations were measured in 2006, 2008, and 2010. The FPG trajectories were identified by latent mixture modeling. The modified Kaplan-Meier method was used to calculate lifetime risk of CVD. Results We identified five distinct FPG trajectories and named them according to FPG range and changing pattern over time: low-stable, moderate-stable, moderate-increasing, elevated-decreasing, and elevated-stable. At index age 35 years, we documented 3110 CVD events in men during 371,219 person-years of follow-up and 357 CVD events in women during 107,447 person-years of follow-up. Among all participants, the elevated-stable FPG pattern experienced the highest lifetime risk of CVD (44.8%, 95% CI: 37.8–51.9%), low-stable pattern was lowest (24.3%, 95% CI: 23.3–25.2%). At index age 55 years, although the elevated-stable and elevated-decreasing FPG patterns had similar original FPG concentrations, individuals with elevated-decreasing pattern (30.0%, 95% CI: 23.9–36.1%) had approximately one-third less lifetime risk of CVD than those with elevated-stable pattern (43.6%, 95% CI: 31.8–55.3%). Conclusions FPG trajectories were significantly associated with the lifetime risk of CVD. Both decrease in FPG over time and consistently lower FPG over 4 years were associated with lower lifetime risk of CVD.